Patents Examined by Adam Weidner
-
Patent number: 11976317Abstract: The present invention provides devices, and a method for preparing the devices, for measuring glucose concentration in a liquid sample. The devices are typically in the form of test strips. The test strips are printed with a reagent varnish comprising glucose oxidase, peroxidase, chromogen, and neutralizer. The chromogen in the reagent varnish changes color when the reagent varnish is exposed to glucose.Type: GrantFiled: April 16, 2018Date of Patent: May 7, 2024Assignee: Sun Chemical CorporationInventors: Quang Minh Thai, Michael Hirthammer
-
Patent number: 11970532Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: May 10, 2019Date of Patent: April 30, 2024Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
-
Patent number: 11969476Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.Type: GrantFiled: April 2, 2021Date of Patent: April 30, 2024Assignee: VISTERRA, INC.Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
-
Patent number: 11969464Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 23, 2023Date of Patent: April 30, 2024Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
-
Patent number: 11965035Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: April 23, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
-
Patent number: 11957698Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.Type: GrantFiled: July 8, 2022Date of Patent: April 16, 2024Assignee: SMITH & NEPHEW, INC.Inventors: Aleksa Jovanovic, Lei Shi, Eric Roche, Paul Renick
-
Patent number: 11958898Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: February 16, 2021Date of Patent: April 16, 2024Assignee: NEW YORK UNIVERSITYInventor: Einar Sigurdsson
-
Patent number: 11952409Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 24, 2023Date of Patent: April 9, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
-
Patent number: 11952419Abstract: Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, SkintS, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.Type: GrantFiled: July 8, 2019Date of Patent: April 9, 2024Assignee: UNIVERSITY OF CONNECTICUTInventor: Laijun Lai
-
Patent number: 11945874Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Patent number: 11944628Abstract: The present disclosure provides compositions and methods for inducing immune tolerance in subjects suffering from metabolic diseases.Type: GrantFiled: May 11, 2018Date of Patent: April 2, 2024Assignee: Duke UniversityInventors: Priya S. Kishnani, Zoheb B. Kazi, Ankit K. Desai
-
Patent number: 11939397Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.Type: GrantFiled: May 29, 2019Date of Patent: March 26, 2024Assignee: Novartis AGInventors: Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
-
Patent number: 11939370Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.Type: GrantFiled: July 11, 2019Date of Patent: March 26, 2024Assignees: VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James E. Crowe, Jr., Pavlo Gilchuk, Alexander Bukreyev
-
Patent number: 11939377Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.Type: GrantFiled: July 11, 2019Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
-
Patent number: 11931384Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.Type: GrantFiled: December 16, 2021Date of Patent: March 19, 2024Assignee: MiMedx Group, Inc.Inventors: Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
-
Patent number: 11932698Abstract: Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-? receptor II (dnTGF?RII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).Type: GrantFiled: August 29, 2019Date of Patent: March 19, 2024Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Qing Dai, Jian Liu, Shuai Yang, Kun Jiang, Yuanyuan Peng, Chen Hu, Shu Wu
-
Patent number: 11926654Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: GrantFiled: March 5, 2019Date of Patent: March 12, 2024Assignee: CENTRO DE INMUNOLOGIA MOLECULARInventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
-
Patent number: 11925662Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.Type: GrantFiled: December 15, 2020Date of Patent: March 12, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Evgeniy Eruslanov, Steven Albelda
-
Patent number: 11919958Abstract: Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “?CD28×?B7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject ?CD28×?B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.Type: GrantFiled: August 19, 2021Date of Patent: March 5, 2024Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
-
Patent number: 11919854Abstract: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.Type: GrantFiled: March 29, 2019Date of Patent: March 5, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CHRU DE LILLE, UNIVERSITE COTE D'AZUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE, JUNIAInventors: Valérie Vouret, Laetitia Douguet, Alina Ghinet, Germain Homerin, Benoît Guy Marie Rigo, Davy Jérémy Baudelet, Xavier Dezitter, Régis Millet, Christophe Furman